Skip to main content


Fig. 1 | International Journal of Retina and Vitreous

Fig. 1

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Fig. 1

Baseline lesion size and treatment cycles. Baseline lesion size corresponded significantly to number of treatment cycles required and decreased visual acuity. TTZ triple combination therapy with zeaxanthin, TT triple combination therapy, VA vision. Baseline VA <20/100 = 20/200 or worse vision (p < 0.0001 for baseline VA >20/100 versus baseline VA <20/100, as well as for 2 or less treatment cycles versus 3 or more treatment cycles)

Back to article page